(2S)-tert-Butyl 3-cyano-2-methyl-4-oxopiperidine-1-carboxylate

Physicochemically, it is a white to off-white crystalline powder with stable performance, melting at 97-99°C and a predicted density of 1.15±0.1 g/cm³. Slightly soluble in polar organic solvents (chloroform, DMSO, methanol), it fits mainstream pharmaceutical synthesis. Its structural design enhances reaction compatibility, laying a solid foundation for subsequent drug synthesis modification.

It complies with pharmaceutical-grade QC standards, with high purity, excellent chiral purity, and strict control of heavy metals/impurities. Tested by HPLC for batch consistency and purified via mature processes, it meets large-scale pharmaceutical production requirements, reducing customer production risks and costs.

Hygroscopic and easy to store/transport, it requires hermetic packaging in pharmaceutical-grade leak-proof containers, stored at 2-8℃ in a cool, dry, well-ventilated environment. Kept away from moisture, heat, strong light, oxidants and acids/alkalis, it can be nitrogen-protected or paired with desiccants to prevent decomposition/racemization.

Widely used in pharmaceutical synthesis, it is a key chiral intermediate for heterocyclic drugs (CNS, analgesics, antibacterials) and high-demand oral small-molecule GLP-1 agonists like Orforglipron (for diabetes/obesity). Its stable structure and versatile groups match Orforglipron’s molecular construction needs, simplifying synthesis and boosting yield. It is a high-potential choice for enterprises pursuing efficient, high-quality new drug R&D and bulk production amid booming GLP-1 demand.